Drugs / LABR-312
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02645799 Comparator | Apr 2016 → Aug 2018 | diabetes mellitus | BIOrest Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LABR-312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02645799 ↗ |
| Route | Intravenous | “administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent” NCT02645799 ↗ |